

**CURRICULUM VITAE****Name:** Prof. Dr. Dr. *h.c.* Lutz F. Tietze**Address:** Institut für Organische und Biomolekulare Chemie Georg-August-Universität  
Tammannstr. 2, 37077 Göttingen**Professional Education**

1961 - 1968	Studies in Chemistry at the University of Kiel and Freiburg
31.3.1966	Diploma in Chemistry
15.7.1968	Ph.D. under the guidance of Prof. Dr. B. Franck "Untersuchungen zur gezielten Oxidation von Laudanosolin-Derivaten" (Selective Oxidation of Laudanosolin-Derivatives).
15.9.1969 - 14.9.1971	Research Associate with Prof. Dr. G. Büchi at the Massachusetts Institute of Technology in Cambridge/USA
1974	Research Associate with Prof. Dr. A.R. Battersby at the University of Cambridge, England
9.7.1975	Habilitation at the University of Muenster. Thesis: "Secologanin, Schluesselverbindung in der Biosynthese der Indol-, Ipecacuanha- und Cinchona-Alkaloide. Untersuchungen zur Biogenese und Synthese" (Secologanin, Key Intermediate in the Biosynthesis of Indole-Ipecacuanha and Cinchona-Alkaloids. Biogenesis and Synthesis). Appointment as "Privatdozent"
1977	Professor at the University of Dortmund.
1978 - 2012 (2008)	Professor (Chair) and Director of the Institute of Organic Chemistry at the Georg-August-University in Goettingen
1983 - 1987 and 1991 - 1995	Dean and Vice Dean of the Faculty of Chemistry at the Georg-August University of Goettingen
Since 2012	Distinguished Research Professor of the State of Lower Saxony

**Personal Data:**

Date of birth:	14.3.1942
Place of birth:	Berlin
Parents:	Dr. Friederich Tietze, Landgerichtsdirektor; Hete-Irene Tietze, geb. Kruse
Marital Status:	Married since 28.12.1966 to Karin Tietze, née Krautschneider. Four children.

**Visiting Professorships:**

Hamburg (1978); Madison, Wisconsin, USA (1982); Strasbourg, France (1995); Sydney, Australia (1999); Bologna, Italy (2001); Paris, France (2003); J.C. Bose Chair Professor, Bhopal, India (2012); Sydney, Australia (2014).

**Awards and Scholarships:**

1968 Ph.D.-Award (Fonds of the Chemical Industry); 1969 Fulbright Scholarship; 1969 Liebig Scholarship (Chemical Industry); 1976 Karl-Winnacker Award (Hoechst); 1982 Literature Prize (Fonds of the Chemical Industry); 1987 Honourable Member of the SAIQO (Chemical Society of Argentina); 1990 Member of the Academy of Science, Goettingen; 1991 Fellowship of the Japanese Society for the Promotion of Science; 1991 Fellow of the Royal Society of Chemistry; 1992 Offer of a Chair at the University of Muenster as successor to Prof. B. Franck (declined). 1994 Awarded the title "Doctor honoris causa" of the University of Szeged, Hungary; 2002 Silver Medal of the University of Szeged, Hungary; 2002 Grignard-Wittig-Award of the Société Française de Chimie, France; 2004 Emil Fischer Gold Medal of the German Chemical Society (GDCh); 2008 Prix Charles Mentzer of the Société de Chimie Thérapeutique, France; 2008 Hevesy Lectureship Award of the GDCh and the Hungarian Chemical Society; 2009 Novartis Lectureship Award; since 2010 corresponding member of the North Rhine-Westphalian Academy of Sciences and the Arts; 2011 UR-Ghatak Gold Medal of the Indian Association for Cultivation of Science; 2014 Honorable Fellow of the Indian Chemical Society (CSRI).

**Functions:**

From 1978 until 1996 and from 1998 until 2008 Director of the Institute of Organic Chemistry, University of Goettingen. From 1996 until 2006 Speaker of the Sonderforschungsbereich 416 (Center of Excellence) "Chemische und biologische Synthese und Transformation von Naturstoffen und Naturstoff-Analoga"; since 1997 President of the "Deutscher Zentralausschuss der Chemie (DZfCh)" (Steering Committee of the German Chemical Societies); since 2012 Distinguished Research Professor of the State of Lower Saxony.

**Research Fields:**

1. Development of selective and efficient as well as ecologically and economically benign synthetic methods and their use in the total synthesis of bioactive natural products and materials.
2. Design of a novel approach for a selective treatment of cancer using the antibody directed enzyme prodrug therapy (ADEPT) and the prodrug monotherapy (PMT) as well as antibody drug conjugates (ADCs).

**Publications:** 469; Patents: 34; Books: 6. One of the books has been translated into English, Japanese, Russian, Korean and Chinese.